Gnana P. Krishnamoorthy

Gnana P. Krishnamoorthy

Auto-generated profile, based on publicly available information

Gnana P. Krishnamoorthy

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2023 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
JFJames A. Fagin
James A. Fagin
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
Iñigo LandaIñigo Landa
Iñigo Landa

13 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LBLaura Boucai
Laura Boucai
MSMahesh Saqcena
Mahesh Saqcena
FKFengshen Kuo
Fengshen Kuo
RGRavinder K. Grewal
Ravinder K. Grewal
NSNicholas Socci
Nicholas Socci
JFJames A. Fagin
James A. Fagin
Purpose: The determinants of response or resistance to radioiodine (RAI) are unknown. We aimed to identify genomic and transcriptomic factors associated with structural responses to RAI treatment of metastatic thyroid cancer, which occur infrequently, and to test whether high MAPK pathway output was associated with RAI refractoriness. Experimental Design: Exceptional response to RAI was defined as reduction of tumor volume based on RECIST v1.1. We performed a retrospective case–control study of genomic and transcriptomic characteristics of exceptional responders (ER; n = 8) versus nonresponders (NR; n = 16) matched by histologic type and stage at presentation on a 1:2 ratio. Results: ER are enriched for mutations that activate MAPK through RAF dimerization (RAS, class 2 BRAF, RTK fusions), whereas NR are associated with BRAFV600E, which signals as a monomer and is unresponsive to negative feedback. ER have a lower MAPK transcriptional output and a higher thyroid differentiation score (TDS) than NR (P < 0.05). NR are enriched for 1q-gain (P < 0.05) and mutations of genes regulating mRNA splicing and the PI3K pathway. BRAFV600E tumors with 1q-gain have a lower TDS than BRAFV600E/1q-quiet tumors and transcriptomic signatures associated with metastatic propensity. Conclusions: ER tumors have a lower MAPK output and higher TDS than NR, whereas NR have a high frequency of BRAFV600E and 1q-gain. Molecular profiling of thyroid cancers and further functional validation of the key findings discriminating ER from NR may help predict response to RAI therapy.

21 July 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
Iñigo LandaIñigo Landa
Iñigo Landa
CTCaitlin Thornton
Caitlin Thornton
BXBin Xu
Bin Xu
JHJacob Haase
Jacob Haase
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
JFJames A. Fagin
James A. Fagin
Mutations in the promoter of the telomerase reverse transcriptase (TERT) gene are the paradigm of a cross-cancer alteration in a noncoding region. TERT promoter mutations (TPM) are biomarkers of poor prognosis in cancer, including thyroid tumors. TPMs enhance TERT transcription, which is otherwise silenced in adult tissues, thus reactivating a bona fide oncoprotein. To study TERT deregulation and its downstream consequences, we generated a Tert mutant promoter mouse model via CRISPR/Cas9 engineering of the murine equivalent locus (Tert−123C>T) and crossed it with thyroid-specific BrafV600E-mutant mice. We also employed an alternative model of Tert overexpression (K5-Tert). Whereas all BrafV600E animals developed well-differentiated papillary thyroid tumors, 29% and 36% of BrafV600E+Tert−123C>T and BrafV600E+K5-Tert mice progressed to poorly differentiated cancers at week 20, respectively. Tert-upregulated tumors showed increased mitosis and necrosis in areas of solid growth, and older animals displayed anaplastic-like features, that is, spindle cells and macrophage infiltration. Murine TPM increased Tert transcription in vitro and in vivo, but temporal and intratumoral heterogeneity was observed. RNA-sequencing of thyroid tumor cells showed that processes other than the canonical Tert-mediated telomere maintenance role operate in these specimens. Pathway analysis showed that MAPK and PI3K/AKT signaling, as well as processes not previously associated with this tumor etiology, involving cytokine, and chemokine signaling, were overactivated. These models constitute useful preclinical tools to understand the cell-autonomous and microenvironment-related consequences of Tert-mediated progression in advanced thyroid cancers and other aggressive tumors carrying TPMs. Implications: Telomerase-driven cancer progression activates pathways that can be dissected and perhaps therapeutically exploited.

24 February 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
AGAnthony Glover
Anthony Glover
BUBrian R. Untch
Brian R. Untch
NSNickole Sigcha-Coello
Nickole Sigcha-Coello
BXBin Xu
Bin Xu
JFJames A. Fagin
James A. Fagin
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function RBM10 mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by RBM10 loss showed pro-migratory and RHO/RAC signaling signatures. RBM10 loss increases cell velocity. Cytoskeletal and ECM transcripts subject to exon inclusion events included vinculin (VCL), tenascin C (TNC), and CD44. Knockdown of the VCL exon inclusion transcript in RBM10-null cells reduced cell velocity, whereas knockdown of TNC and CD44 exon inclusion isoforms reduced invasiveness. RAC1-GTP levels were increased in RBM10-null cells. Mouse HrasG12V/Rbm1OKO thyrocytes develop metastases that are reversed by RBM10 expression or by combined knockdown of VCL, CD44, and TNC inclusion isoforms. Thus, RBM10 loss generates exon inclusion in transcripts regulating ECM–cytoskeletal interactions, leading to RAC1 activation and metastatic competency. Moreover, a CRISPR-Cas9 screen for synthetic lethality with RBM10 loss identified NFκB effectors as central to viability, providing a therapeutic target for these lethal thyroid cancers.

28 December 2024 in Scientific Data
Verified
Journal Article
Open access
PDF file
LLLu Li
Lu Li
WJWenhao Jiang
Wenhao Jiang
WWWenjun Wei
Wenjun Wei
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
PHPingping Hu
Pingping Hu
YSYaoting Sun
Yaoting Sun
Thyroid nodules are a common endocrine condition with an increasing incidence over the decades. Data-independent acquisition has been widely utilized in discovery proteomics to identify disease biomarkers and therapeutic targets. To analyze the thyroid disease-related proteome in a high-throughput, reproducible and reliable manner, we introduce thyroid-specific peptide spectral libraries. Here, we generated four deep-coverage libraries through four mass spectrometers comprising Q Exactive HF, Orbitrap Exploris 480, ZenoTOF 7600, and timsTOF Pro. These libraries encompass over 215,000 precursors, 172,000 peptides, and 12,000 proteins, derived from 245 tissue samples across nine histological types and 50 cell lines across six histological types. Moreover, the spectral libraries are applied to nine types of thyroid samples to facilitate the exploration of disease-specific proteins. Our spectral libraries serve as a valuable resource for analyzing thyroid protein content, facilitating deeper insights into thyroid disorders.

16 August 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
ANAradhya Nigam
Aradhya Nigam
GKGnana P. Krishnamoorthy
Gnana P. Krishnamoorthy
WCWalid K. Chatila
Walid K. Chatila
KBKatherine Berman
Katherine Berman
MSMahesh Saqcena
Mahesh Saqcena
BUBrian R. Untch
Brian R. Untch